New York State Teachers Retirement System Acquires 108,800 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

New York State Teachers Retirement System raised its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 96.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 221,890 shares of the biotechnology company's stock after buying an additional 108,800 shares during the period. New York State Teachers Retirement System owned about 0.09% of ADMA Biologics worth $4,402,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. KBC Group NV increased its holdings in ADMA Biologics by 11.5% during the first quarter. KBC Group NV now owns 11,217 shares of the biotechnology company's stock valued at $223,000 after buying an additional 1,154 shares during the last quarter. Lisanti Capital Growth LLC increased its holdings in ADMA Biologics by 75.8% during the first quarter. Lisanti Capital Growth LLC now owns 308,440 shares of the biotechnology company's stock valued at $6,119,000 after buying an additional 132,970 shares during the last quarter. Tsfg LLC purchased a new stake in ADMA Biologics during the first quarter valued at approximately $51,000. Allspring Global Investments Holdings LLC increased its holdings in ADMA Biologics by 7.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 3,048,946 shares of the biotechnology company's stock valued at $59,211,000 after buying an additional 207,097 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its holdings in ADMA Biologics by 48.2% during the first quarter. Robeco Institutional Asset Management B.V. now owns 258,609 shares of the biotechnology company's stock valued at $5,131,000 after buying an additional 84,125 shares during the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James Financial upped their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research report on Thursday, May 8th.

Insider Buying and Selling at ADMA Biologics

In other news, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction on Monday, June 9th. The shares were sold at an average price of $20.96, for a total value of $419,200.00. Following the sale, the director owned 94,830 shares of the company's stock, valued at approximately $1,987,636.80. This represents a 17.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Steve Elms sold 194,749 shares of the firm's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the transaction, the director directly owned 87,330 shares in the company, valued at $1,767,559.20. This represents a 69.04% decrease in their position. The disclosure for this sale can be found here. Insiders sold 464,621 shares of company stock worth $9,644,269 over the last 90 days. 3.50% of the stock is owned by insiders.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA traded up $0.13 during midday trading on Thursday, reaching $18.47. 2,103,391 shares of the company were exchanged, compared to its average volume of 3,677,577. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22. The business's fifty day moving average is $19.88 and its two-hundred day moving average is $18.73. ADMA Biologics Inc has a one year low of $10.21 and a one year high of $25.67. The stock has a market cap of $4.41 billion, a PE ratio of 21.73 and a beta of 0.43.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The company had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. During the same quarter in the prior year, the company posted $0.08 EPS. ADMA Biologics's revenue was up 40.2% compared to the same quarter last year. As a group, analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.